PROF · Profound Medical Corp.
Market Cap
$210.43M
Shares
36.53M
Volume · Sep 30
106.88K
Avg daily vol (3M)
118.74K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$5.80
Open$5.71
Day$5.65–5.91
52W close$4.89–8.65
Avg vol 30d119K
Short int1.6M · 4.3% float · 12.3d
Short vol37%
Last earningsAug 6, 2026
DataJan 2020–Sep 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Oct 22, 2026
Est · unconfirmed
· in 3 wks
filed Aug 6, 2026
call held Mar 5, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$19.09M
Trailing 12 months
Net income (TTM)
−$32.74M
Trailing 12 months
Revenue growth YoY
+12.3%
Year over year
Operating margin
-185.3%
Trailing 12 months
P / E (TTM)
3.8
Trailing earnings · reciprocal yield 26.2%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$29.26M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+21.0%
Year over year · more shares
Price change (1Y)
+12.2%
Trailing year
Short interest
4.3%
Latest settlement · 12.3 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 16.3 · calm
Equity put/call 0.53
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−15%
below
Price vs 50-day avg
−14%
below
RSI (14)
40
neutral
MACD trend
Positive
52-week position
24%
mid-range
Momentum
relative strength
1-month return
−15%
trailing
6-month return
−10%
trailing
YTD return
−26%
this year
Relative strength
−22%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $7 › 200d $7 — 200d above 50d
Institutional flow
Distributing
-2% holders QoQ · +5 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
4.30% of float · ▼ -3.0% MoM · 12.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
57 holders — mid 3-yr range
Squeeze score
64
elevated · 0–100
Fundamentals
Revenue growth
+51%
Y/Y
Gross margin
71%
expanding
EPS growth
+26%
Y/Y
Free cash flow
$-38.4M
Balance sheet
$55.2M
net cash
Quant / Vol
risk profile
Volatility
67%
annualized · 1-yr
Max drawdown
−42%
past year
ATR
5.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 6, 2026
Total revenue
· full-year 2026
Initiated
$25M
prior FY $16.1M
midpoint +55.3% Y/Y
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−15%
Bearish
Price vs 50-day avg
−14%
Bearish
RSI (14)
40
Neutral
MACD trend
Positive
Bullish
52-week position
24%
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $7 › 200d $7 — 200d above 50d
Institutional flow
Distributing
-2% holders QoQ · +5 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
4.30% of float · ▼ -3.0% MoM · 12.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
57 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $5
Now $6 · 24%
Range high $9
vs 200-day avg -15%
vs 50-day avg -14%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PROF
this stock
Profound Medical Corp.
|
$210.43M | -26.3% | +50.7% | — | 4.3% |
|
ABT
Abbott Laboratories
|
$174.90B | -21.1% | +5.7% | 28.1 | 1.1% |
|
MDT
Medtronic plc
|
$113.38B | -10.2% | +8.4% | 21.8 | 1.3% |
|
SYK
Stryker Corp
|
$104.47B | -21.6% | +11.2% | 28.2 | 2.0% |
|
BSX
Boston Scientific Corp
|
$63.59B | -54.2% | +12.5% | 17.8 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PROF | +1.1% | -14.7% | -9.9% | -14.7% | -26.3% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | +1.8% | -14.8% | -22.1% | -14.1% | -38.1% |